New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
10:15 EDTINSMInsmed drops, bounces, after Arikayce Phase 2 trial results
The stock is down over 10% at time of writing to $16.46 after Arikayce did not achieve the primary endpoint in Phase 2 trial. Shares hit a low of $15.69, currently support, and then bounced. Resistance is at the session high at $17.38. Piper Jaffray noted that the 'much more meaningful' secondary endpoint was met.
News For INSM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
13:54 EDTINSMInsmed personnel strong, says Piper Jaffray
After attending Insmed's analyst event, Piper says that the company has assembled a strong development and commercial team . The firm adds that the company has forged unique relationships with specialists and patients. It keeps an Overweight rating on the shares.
March 23, 2015
09:06 EDTINSMInsmed appoints Eugene Sullivan as Chief Medical and Scientific Officer
Subscribe for More Information
March 20, 2015
09:25 EDTINSMInsmed to host analyst and investor day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use